Author

T. D. Wu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

Z. Modrusan· 2 shared A. A. Lo· 1 shared A. Ashkenazi· 1 shared A. Le Thomas· 1 shared A. Ritter· 1 shared A. Wallace· 1 shared A. Yang· 1 shared C. B. Carbone· 1 shared

Activity by Year

2021-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Z. Modrusan

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Surveillance of in situ tumor arrays reveals early environmental control of cancer immunity

G. Ortiz-Munoz, M. Brown, C. B. Carbone, J. Pechuan Jorge, A. Ritter, D. Orlova, S. R. Mantri, A. Yang, J. Doerr, S. Mariathasan, Y. Wang, S. Turley, C. Gomez-Roca, C. Eduardo de Andrea, D. Spigel, , C. Moussion

This study introduces STAMP, a method to monitor tumor-immune dynamics in vivo, showing immune phenotypes evolve over time and correlate with therapeutic response.

bioRxiv · May 27, 2021 · PreprintCancer Biology

Noncanonical mRNA decay by the endoplasmic-reticulum stress sensor IRE1α promotes cancer-cell survival

A. Le Thomas, E. Ferri, S. Marsters, J. M. Harnoss, Z. Modrusan, W. Li, J. Rudolph, W. Wang, T. D. Wu, P. Walter, A. Ashkenazi

The paper identifies a noncanonical mRNA decay process, RIDDLE, mediated by IRE1α oligomers in cancer cells, which promotes survival by degrading mRNAs without XBP1-like endomotifs.

bioRxiv · Mar 16, 2021 · PreprintCancer Biology

Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies

A. A. Lo, A. Wallace, D. Oreper, N. Lounsbury, C. Havnar, X. Pechuan-Jorge, T. D. Wu, R. Bourgon, R. Jones, K. Krogh, G.-Y. Yang, O. A. Zill

The paper analyzes tumor evolution across cancer types to identify factors affecting neoantigen targeting in immunotherapy.

bioRxiv · Mar 15, 2021Cancer Biology